Meeting Report
Nuances in the Management of Aggressive Lymphomas
Presented by Paul A. Hamlin, MD, and Michelle Wisniewski, MS, PA-C
Memorial Sloan Kettering Cancer Center, New York New York
Presenters’ disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2017;8:279–284 |
https://doi.org/10.6004/jadpro.2017.8.3.11 |
© 2017 Harborside Press®
ABSTRACT
Treatment for both Hodgkin and Non-Hodgkin lymphoma now includes chemotherapy, targeted therapy, and new immunotherapies. As research continues to shine the light on tumor genetics, clinical variability, and new treatment approaches, advanced practitioners need to translate this information in the management of aggressive lymphomas.
For access to the full length article, please
sign in.
